NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
UPC
Universe Pharmaceuticals Inc.
There isn't enough reported data to score UPC yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
UPC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
UPC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
UPC PE Valuation
UPC has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
UPC Forward outlook
There aren't enough analyst estimates for UPC to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over UPC in the latest year-over-year earnings comparison.
UPC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2024 | -$3,054.00 | -$1,206.00 |
| Q3 2023 | -$1,020.00 | +$420.00 |
| Q3 2022 | -$1,440.00 | -167% |
UPC has swung to a loss: it lost $3,054.00 per share over the past year, after a profit the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
UPC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $23M | +66% |
| Q1 2024 | $12.9M | -30% |
| Q3 2023 | $13.8M | -13% |
| Q1 2023 | $18.5M | -24% |
| Q3 2022 | $15.9M | -67% |
| Q3 2021 | $48M | +213% |
| Q3 2020 | $15.4M | -7.6% |
| Q1 2020 | $15.4M | +85% |
UPC has the edge over NVO in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -35% | +36 points |
| Q1 2024 | -14% | -25 points |
| Q3 2023 | -27% | -55 points |
| Q1 2023 | 0.8% | -33 points |
| Q3 2022 | -71% | -105 points |
| Q1 2022 | 11% | -18 points |
| Q3 2021 | 28% | -1 points |
| Q3 2020 | 34% | -0.2 points |
UPC's operating margin was −35% last quarter, up 36 points from the same quarter a year ago, near the bottom of its range since 2018.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
UPC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$9.7M | -$6M |
| Q1 2024 | -$2.5M | -151% |
| Q3 2023 | -$3.7M | +$3.7M |
| Q1 2023 | $4.8M | -21% |
| Q3 2022 | -$7.5M | -$5M |
| Q3 2021 | -$2.5M | -182% |
| Q3 2020 | $3M | -54% |
| Q1 2020 | $3M | -7.6% |
UPC's free cash flow was −$11M over the past year, against −$874,723 the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over UPC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
UPC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +35 shares |
| 1 year | +0.6% | +35 shares |
UPC has 6,077 diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
| Q1 2019 | — |
| Q3 2018 | — |
| Q1 2018 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
UPC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -0.3x | Net Cash |
UPC has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
UPC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 1.6 | Oversold |
UPC's weekly RSI is 36 (neutral) and its Stochastic is 2 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
UPC PE vs Healthcare Sector
| Metric | UPC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
UPC has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over UPC on trend strength, trading above more of its moving averages.
UPC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.26 | 53% below |
| 20 week MA | $4.17 | 63% below |
| 50 week MA | $3.71 | 59% below |
| 100 week MA | $5.34 | 71% below |
| 200 week MA | $665.0 | 100% below |
UPC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over UPC on returns for 2026, with the stronger performance.
UPC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14,616.0 | $5,940.0 | -59% |
| 2022 | $5,940.0 | $5,796.0 | -2.4% |
| 2023 | $5,796.0 | $1,206.0 | -79% |
| 2024 | $1,206.0 | $24.9 | -98% |
| 2025 | $24.9 | $5.62 | -77% |
| 2026 YTD | $5.62 | $1.53 | -73% |
UPC has finished every year since 2021 lower, and it's down 73% so far in 2026.